← Leaderboards
Paul P. Carbone
University Of Wisconsin Madison
$972,813
Attributed
$972,813
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$972,813 · 5
By mechanism
U01$457,202 · 1
P30$289,556 · 1
M01$226,055 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Howard H Bailey$27,057,671
- Ajit K Verma$7,705,981
- Sandra E Ward$5,320,036
- Joan H Schiller$7,395,575
- James A Stewart$6,121,809
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchDifluoromethylornithineHuman SubjectCancer PreventionSkin NeoplasmsHuman Therapy EvaluationDrug Screening /EvaluationChemopreventionBiomarkerOral AdministrationTransplantationDosage FormsPharmacokineticsBlood ChemistryCarcinogenesis InhibitorClinical Trial Phase IPolyaminesSkin Disorder ChemotherapySkin PharmacologyTherapy ComplianceUrinary Tract NeoplasmsBiomedical FacilityBiopsyBone Marrow Transplantation
Grant awards (11)
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE$106,600
M01 · FY2002 · RR
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE$106,600
M01 · FY2001 · RR
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE$12,855
M01 · FY2001 · RR
CHEMOPREVENTION OF SKIN CANCER--DFMO PHASE 3 TRIAL$457,202
U01 · FY2000 · CA
CORE--DEVELOPMENTAL FUNDS$289,556
P30 · FY2000 · CA
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE$0
M01 · FY2000 · RR
DIFLUOROMETHYLORNITHINE FOR CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT$0
M01 · FY2000 · RR
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE$0
M01 · FY2000 · RR
BIOAVAILABLITY OF ORAL LIQUID AND TABLET FORMS OF DIFLUOROMETHYLORNITHINE$0
M01 · FY2000 · RR
BIOAVAILABLITY OF ORAL LIQUID AND TABLET FORMS OF DIFLUOROMETHYLORNITHINE$0
M01 · FY2000 · RR
DIFLUOROMETHYLORNITHINE FOR CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT$0
M01 · FY2000 · RR